Such forward-looking statements may include, without limitation, statements about the combination of Mylan N.V. (“Mylan”) with Pfizer’s off-patent branded and generic established medicines business (the “Upjohn Business”) in a Reverse Morris Trust transaction, after which the combined company was renamed Viatris (“Combination”), the benefits and synergies of the Combination or our global restructuring program, future opportunities for the Company and its products and any other statements regarding the Company’s future operations, financial or operating results, capital allocation, dividend policy, debt ratio, anticipated business levels, future earnings, planned activities, anticipated growth, market opportunities, strategies, competitions, and other expectations and targets for future periods.